Immune-Onc has licensed research from University of Texas, Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center.
US-based biopharmaceutical company Immune-Onc Therapeutics was selected on Wednesday to join StartX, the accelerator affiliated with Stanford University, as part of the Med Accelerator Summer 2017 program.
StartX Med is a medical and life science strand of the StartX accelerator, from which 120 companies have raised $740m and received seven US regulatory approvals in the past four years. StartX has historically accepted 8% of applicants from the Stanford network.
Founded in 2016, Immune-Onc is working on a range of immuno-oncology drugs and treatment options licensed from a variety of institutions.
In April this year, Immune-Onc partnered University of Texas Health Science Center at Houston and University of Texas Southwestern Medical Center, gaining exclusive rights to develop and commercialise its immunotherapy treatments for cancer and other diseases.
In March, the company entered a licensing agreement with Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center for biotherapeutics with applications in cancer immunotherapy and other diseases.
In September 2016, Immune-Onc raised $6m in a series A round featuring Fame Mount and CLI Ventures.
Charlene Liao, co-founder and chief executive officer of Immune-Onc, said: “We are honoured and excited to be selected by StartX, one of the leading accelerators in the world. This is a great opportunity for Immune-Onc to leverage the powerful networks, resources and funding available through StartX.
“We look forward to joining StartX and contributing to this prestigious community.”
